BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...

In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

Jan 31 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25 ...

A Quick Take On Metsera, Inc. Metsera, Inc. (NASDAQ:MTSR) has filed to raise $275 million in an IPO of its common stock, according to SEC S-1/A registration information. The firm is a clinical ...